Karim Fizazi, MD, PhD, is a medical oncologist at Institut Gustave Roussy, Paris, France, and a full Professor in Oncology at the University of Paris Sud in Villejuif, France. He attained his medical degree in 1995. In 1997, he completed a fellowship at Institut Gustave Roussy. After a visiting professorship at the MD Anderson Cancer Center in Houston, USA, from 1999 to 2001, where he was working on preclinical models of bone metastases from prostate cancer, he gained his PhD in Molecular Oncology in 2003. He was Head of the Department of Cancer Medicine at Institut Gustave Roussy from 2005 to 2018 and he was promoted to Professor at the University of Paris Sud in 2009. He is currently leader of the Medical Oncology subgroup of the French Groupe d’étude des tumeurs urogénitales (GETUG) and President of the Groupe d'Etude Français des Carcinomes de site Primitif Inconnu (GEFCAPI). Professor Fizazi is associate editor of European Journal of Cancer and consulting editor of European Urology. He has authored more than 350 peer-reviewed articles.
Amongst his major achievements, Professor Fizazi demonstrated in 2010 the role of denosumab for the prevention of complications of bony metastases from prostate cancer. In 2015, he established the role of early chemotherapy in preventing relapse in men with localised prostate cancer at high-risk for relapse in the GETUG 12 trial. Professor Fizazi is Chair of two major pivotal trials testing next-generation androgen receptor axis targeting agents: LATITUDE, which demonstrated in 2017 the impact of abiraterone on survival in men with de novo metastatic prostate cancer; and ARAMIS, which is currently testing darolutamide, a drug that was first tested by Professor Fizazi in Phase 1 trials, in men with non-metastatic castrate-resistant prostate cancer. In testicular cancer, Professor Fizazi established in 2014 a new standard of care for young patients with poor-prognosis germ-cell tumours, thanks to an individualised algorithm of treatment in the GETUG 13 trial, although no significant progress had been provided for these patients in the previous 25 years.
To push forward clinical research on prostate cancer in Europe, Professor Fizazi created the Prostate Cancer Consortium in Europe (PEACE) in 2013. He is now Head of the two first large PEACE European academic Phase 3 trials: PEACE-1 (testing abiraterone and local radiotherapy in de novo metastatic prostate cancer), which has completed accrual; and PEACE-2 (testing cabazitaxel and pelvic radiotherapy in very high-risk localised prostate cancer). The PEACE-4 trial, which is testing the roles of aspirin and statins in castration-resistant prostate cancer, is also to be launched in early 2019.
Preparation date: January 2019 - Zinc code: PHEM/ONCS/1018/0002f